← Trials/Trial dossier/NCT04417582
Life Style Modification Medical and Surgical Management in Patients With Obesity
Evaluation of Life Style Modification Medical and Surgical Treatment Modalities in Patients With Obesity: An Observational Study
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
1
Enrollment
1,000
estimated
Study population
Bariatric Surgery, Obesity / overweight
Key I/E criterion
•BMI 18-65
Primary endpoints
•Weight loss•Metabolic improvement
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
obese patients refered to our tertiary center for obesity evaluation or treatment
Inclusion criteria
Body mass index over 30 kg/m2 age between 18-65 years
Exclusion criteria
active malignancy pregnancy during involvement period chronic inflamatuar diseases
Endpoints (3)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
1 endpointweight loss
Time frame:6 months interval
threshold achievement, improvement
Glycemic / diabetes
1 endpointmetabolic improvement
Time frame:6 months interval
change from baseline, improvement
Cardiometabolic biomarkers
1 endpointmetabolic improvement
Time frame:6 month
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.